AI Article Synopsis
- Rheumatoid arthritis (RA) is linked to an increased risk of thyroid dysfunction, particularly hypothyroidism, according to a systematic review of 29 studies involving over 35,000 patients with RA.
- The review utilized comprehensive literature searches and calculated pooled odds ratios to compare the risk of thyroid issues between RA and non-RA patients.
- The findings highlight the need for regular thyroid function testing in RA patients and suggest that further research is needed to better understand the relationship between RA and thyroid dysfunction.
Article Abstract
Objective: Rheumatoid arthritis (RA) is an autoimmune disorder. Multiple studies have investigated the risk of thyroid dysfunction in patients with RA but have reached conflicting conclusions. This systematic review aimed to determine whether patients with RA are at higher risk of thyroid dysfunction.
Methods: We comprehensively reviewed online literature databases, including PubMed, Scopus, Embase, and the Cochrane Library, from their respective inception dates to March 25, 2022. Studies that provided data on at least one case of thyroid dysfunction in RA patients and their controls were included. Based on these data, we calculated pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for thyroid dysfunction in RA and non-RA patients.
Results: Twenty-nine studies met the inclusion criteria, involving a total of 35,708 patients with RA. The meta-analysis showed that, compared with non-RA patients, RA patients had an increased risk of developing thyroid dysfunction, particularly hypothyroidism (OR 2.25, 95% CI 1.78-2.84). Subgroup analysis suggested that study type and sample source of control group were the source of heterogeneity.
Conclusions: Patients with RA are at increased risk of developing thyroid dysfunction, especially hypothyroidism. Routine biochemical examination of thyroid function in RA patients should be strengthened. Larger prospective studies are needed to explore the causal relationship between RA and thyroid dysfunction, and to investigate the impact of thyroid dysfunction on RA disease activity, drug efficacy, and medication safety.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022331142.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608862 | PMC |
| http://dx.doi.org/10.3389/fendo.2022.1015516 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low maternal iodine intake and subsequent risk of pharmacologically treated hypertension: A population-based prospective cohort study.
Clin Nutr
January 2025
Department of Food Safety, Centre of Sustainable Diets, Norwegian Institute of Public Health, P.O. Box 222, NO-0213 Oslo, Norway. Electronic address:
Background & Aims: Iodine deficiency is linked to multiple adverse health outcomes, but there is scarce knowledge regarding iodine intake and development of chronic hypertension. We aimed to investigate the prospective association between habitual dietary iodine intake and pharmacologically treated hypertension in mothers up to 10 years after delivery.
Methods: The present study is based on data from an ongoing pregnancy cohort and includes 58,629 women without thyroid dysfunction and hypertension at baseline.
Evaluation of iodine and selenium level and thyroid functions in patients with cystic fibrosis.
J Pediatr Endocrinol Metab
January 2025
Department of Pediatric Pulmonology, Dicle University, Diyarbakır, Türkiye.
Objectives: There is limited research on thyroid function in pediatric patients with cystic fibrosis (pwCF). This study aimed to determine the frequency of thyroid dysfunction in children and adolescents with CF and to evaluate iodine deficiency and selenium status in pwCF.
Methods: Sixty-two CF patients and 62 control subjects were evaluated.
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom.
J Gastroenterol Hepatol
January 2025
Department of Pharmacology, Hepatology and Molecular Medicine Lab, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India.
Background: Resmetirom, the first FDA-approved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined with lifestyle modifications, improves NASH resolution and reduces fibrosis by at least one stage. Low thyroid hormone (T) levels are linked to a higher risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). Epidemiological studies have confirmed the positive correlation between hypothyroidism and MASLD.
View Article and Find Full Text PDFClinical features and factors associated with outcomes of antibody-negative autoimmune encephalitis in patients requiring intensive care.
Crit Care
January 2025
Department of Neuro-Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background And Objectives: Antibody-negative autoimmune encephalitis (AE) is a form of encephalitis characterized by the absence of detectable autoimmune antibodies, despite immunological evidence. However, data on management of patients with antibody-negative AE in the intensive care unit (ICU) are limited. This study aimed to explore the characteristics and subtypes of antibody-negative AE, assess the effects of immunotherapy, and identify factors independently associated with poor functional outcomes in patients requiring intensive care.
View Article and Find Full Text PDFThe use of hyaluronic acid fillers in patients with autoimmune endocrinopathies; in particular, women with Hashimoto's disease - hints for aesthetic doctors.
Prz Menopauzalny
December 2024
Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland.
The increase of the incidence of autoimmune diseases and, at the same time, a significant surge in the number of regenerative/anti-aging medicine treatments carried out, raises the need to systematise the current knowledge on the safety of the use of hyaluronic acid fillers in patients with autoimmune diseases and to frame management guidelines for aesthetic doctors. One of the most prevalent autoimmune diseases is chronic lymphocytic thyroiditis, so-called Hashimoto's disease, which affects one in every 5-10 women who visit a regenerative medicine doctor. Women in the perimenopausal and menopausal period, aged 40-54 years, were the single largest target group for aesthetic treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!